The recent launch will help pharmaceutical and life sciences advertisers to proactively engage audiences at critical decision points in the diagnosis and treatment journey.
Swoop, a provider of custom direct-to-consumer (DTC) and healthcare provider (HCP) audiences, launched its portfolio of predictive AI targeting to help pharmaceutical and life sciences advertisers proactively engage audiences at critical decision points in the diagnosis and treatment journey.
Swoop President, Scott Rines, said, “Swoop’s first-to-market predictive AI targeting allows brands to further refine their healthcare marketing, helping advertisers fill critical information gaps in the patient and provider journey. While historically, real world data has been used to target based on what happened in the past, predictive AI targeting allows advertisers to peer into the future and engage audiences based on what likely will happen in the moments that matter from pre-diagnosis to living with the condition.”
“The healthcare journey, from initial consultation to diagnosis, treatment and continuing care, is multifaceted, intricate and unique for every patient. Pharmaceutical and life sciences brands face distinct challenges during commercialization, grappling with efficiently reaching and effectively engaging the right audience at the right decision-point. Swoop’s predictive segments address these challenges, providing marketers with a new set of tools to optimize targeting, which leads to better patient outcomes, higher conversion and Rx lift, ” Rines added.
Building on its predictive AI adherence targeting launched in September 2023, Swoop’s new audiences allow healthcare marketers to target patients and providers prior to a diagnosis, those most likely to adopt a newly launched therapy or progress to a new line of treatment and those with ideal formulary coverage.
Using advanced algorithms and real-world data, Swoop’s predictive AI targeting develops highly precise segments for activation at five critical inflection points in the diagnosis and treatment journey, linking patients and providers, for converged targeting.
